“These results support ravulizumab as a long-term treatment for people with [atypical hemolytic uremic syndrome] aHUS,” Bradley P. Dixon, professor of pediatrics and medicine and head of the renal section of the department of pediatrics at the University of Colorado School of Medicine, and colleagues wrote in Kidney Medicine.